Dexcom (NSDQ:DXCM) beat expectations on Wall Street with its fourth quarter and full year financial results, growing its quarterly revenue 29% compared to the same period last year.
The San Diego, Calif.-based company posted a net loss of -$9.4 million, or -11¢ per share, on sales of $221 million for the 3 months ended Dec. 31. Adjusted to exclude one-time items, earnings per share were 10¢, handily topping consensus on The Street, where analysts were looking for sales of $215.9 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Dexcom beats The Street with Q4 sales, earnings appeared first on MassDevice.